Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
TRVI · Why this verdict
Why Trevi Therapeutics (TRVI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Trevi Therapeutics is a pre-commercial biotechnology company with 63% analyst-implied upside to $20.79 and strong technical momentum in a breakout setup, but its cash-burning profile, below-quality-floor metrics, and high implied volatility of 188% reflect the binary risk inherent in a clinical-stage biotech with no approved products.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With cash-burning status noted in the quality assessment — free cash flow negative — and ROE, ROA, gross margin, and net margin all at zero in the scoring, Trevi lacks any demonstrable profitability metrics, placing it in the below-quality-floor category that reflects the pre-revenue nature of a clinical-stage company. Quality breakdown | Cash runway extends beyond 18 months based on quarterly cash burn rate relative to the balance sheet, ensuring the company can reach its next clinical milestone without requiring dilutive financing at current low prices. | →Stable |
| CounterCash burning is expected for a clinical-stage biotech; the relevant metric is whether cash on hand covers the runway to a value-creating event, not whether the company is currently profitable. | ||
Implied volatility at 188% — among the highest in the medical universe — combined with a put/call ratio of 1.87 reflects the market's pricing of an imminent binary outcome, meaning options traders expect an extremely large price move in either direction tied to a clinical or regulatory event. Risk breakdown | Implied volatility falls below 100% after a positive binary event resolution, indicating that the uncertainty has been resolved in the bull case and the stock is transitioning from a catalyst-driven to a commercial execution story. | →Stable |
| CounterAt 188% implied volatility, options pricing creates extreme hedging costs; any catalyst delay rather than outright failure could deflate the premium sharply even without a negative clinical outcome, trapping both long and short holders. | ||
Analysts project 63% upside from the current price of $14.66 to a consensus target of $20.79, and the risk/reward ratio of 5.97x implies that informed research analysts see a strongly asymmetric outcome weighted toward the upside based on their assessment of the clinical program's probability of success. Sentiment breakdown | Stock price appreciates at least 25% toward $18.00 within 12 months as clinical progress updates drive upward analyst estimate revisions and the consensus target is maintained or increased. | →Stable |
| CounterBiotech analyst price targets are derived from probability-weighted outcomes of binary clinical events; a single clinical failure would eliminate the upside case and potentially cause a decline well below the current $13.63 stop-loss level. | ||
Trevi is displaying a golden cross with RSI at 54, bullish MACD, rising on-balance volume, and above all major moving averages at a momentum score of 7.3 out of 10 — a technically strong setup suggesting institutional positioning ahead of an anticipated catalyst. Momentum breakdown | Price sustains above the 200-day moving average for at least 5 consecutive months with on-balance volume continuing its upward trend, confirming that institutional accumulation is ongoing rather than momentum-only driven. | →Stable |
| CounterTechnical breakouts in small-cap biotech names often reflect speculative positioning ahead of catalysts and can reverse violently on clinical disappointments or data interpretations that do not meet market expectations. | ||
With cash-burning status noted in the quality assessment — free cash flow negative — and ROE, ROA, gross margin, and net margin all at zero in the scoring, Trevi lacks any demonstrable profitability metrics, placing it in the below-quality-floor category that reflects the pre-revenue nature of a clinical-stage company.
→StableQuality breakdown
- Expectation
- Cash runway extends beyond 18 months based on quarterly cash burn rate relative to the balance sheet, ensuring the company can reach its next clinical milestone without requiring dilutive financing at current low prices.
CounterCash burning is expected for a clinical-stage biotech; the relevant metric is whether cash on hand covers the runway to a value-creating event, not whether the company is currently profitable.
Implied volatility at 188% — among the highest in the medical universe — combined with a put/call ratio of 1.87 reflects the market's pricing of an imminent binary outcome, meaning options traders expect an extremely large price move in either direction tied to a clinical or regulatory event.
→StableRisk breakdown
- Expectation
- Implied volatility falls below 100% after a positive binary event resolution, indicating that the uncertainty has been resolved in the bull case and the stock is transitioning from a catalyst-driven to a commercial execution story.
CounterAt 188% implied volatility, options pricing creates extreme hedging costs; any catalyst delay rather than outright failure could deflate the premium sharply even without a negative clinical outcome, trapping both long and short holders.
Analysts project 63% upside from the current price of $14.66 to a consensus target of $20.79, and the risk/reward ratio of 5.97x implies that informed research analysts see a strongly asymmetric outcome weighted toward the upside based on their assessment of the clinical program's probability of success.
→StableSentiment breakdown
- Expectation
- Stock price appreciates at least 25% toward $18.00 within 12 months as clinical progress updates drive upward analyst estimate revisions and the consensus target is maintained or increased.
CounterBiotech analyst price targets are derived from probability-weighted outcomes of binary clinical events; a single clinical failure would eliminate the upside case and potentially cause a decline well below the current $13.63 stop-loss level.
Trevi is displaying a golden cross with RSI at 54, bullish MACD, rising on-balance volume, and above all major moving averages at a momentum score of 7.3 out of 10 — a technically strong setup suggesting institutional positioning ahead of an anticipated catalyst.
→StableMomentum breakdown
- Expectation
- Price sustains above the 200-day moving average for at least 5 consecutive months with on-balance volume continuing its upward trend, confirming that institutional accumulation is ongoing rather than momentum-only driven.
CounterTechnical breakouts in small-cap biotech names often reflect speculative positioning ahead of catalysts and can reverse violently on clinical disappointments or data interpretations that do not meet market expectations.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 81)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 8.9 |
| erm sentiment | 5.2 |
- ▸Analyst upside: 35%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.5 |
| growth rank | 5.0 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 0.9 |
| 52w position | 9.5 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.7 |
| days to cover | 0.5 |
| volatility | 0.5 |
| put call | 10.0 |
| implied vol | 1.7 |
| max pain risk | 3.0 |
| beta | 6.8 |
| debt equity | 8.4 |
- ▸High IV: 70%
- ▸Above max pain $6
Catalyst
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (0)
none
Reward-to-Risk
1.16
Upside
+17.4%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $2.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.2<1.5@spot.
The strongest dimensions are Value at 7.5, Momentum at 6.6, and Sentiment at 6.3; the weakest are Quality at 1.5, Technical at 3.8, and Risk (lower is worse) at 4.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.16 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analysts project 63% upside from the current price of $14.66 to a consensus target of $20.79, and the risk/reward ratio of 5.97x implies that informed research analysts see a strongly asymmetric outcome weighted toward the upside based on their assessment of the clinical program's probability of success.
Trip ifAnalyst consensus price target falls below $15.00 — near the current $14.66 price — indicating professional models are reducing their valuation of the clinical pipeline below current market levels.
- P2Trevi is displaying a golden cross with RSI at 54, bullish MACD, rising on-balance volume, and above all major moving averages at a momentum score of 7.3 out of 10 — a technically strong setup suggesting institutional positioning ahead of an anticipated catalyst.
Trip ifPrice drops below $13.63 stop-loss level, more than 7% below current price, confirming the technical breakout has failed and momentum reversed.
- P3With cash-burning status noted in the quality assessment — free cash flow negative — and ROE, ROA, gross margin, and net margin all at zero in the scoring, Trevi lacks any demonstrable profitability metrics, placing it in the below-quality-floor category that reflects the pre-revenue nature of a clinical-stage company.
Trip ifQuarterly cash burn increases by more than 30% versus the prior quarter without a corresponding milestone achievement, indicating accelerating cash consumption that threatens the runway to the next value-creating event.
- P4Implied volatility at 188% — among the highest in the medical universe — combined with a put/call ratio of 1.87 reflects the market's pricing of an imminent binary outcome, meaning options traders expect an extremely large price move in either direction tied to a clinical or regulatory event.
Trip ifImplied volatility falls below 60% without a positive catalyst announcement, suggesting the binary option premium has deflated due to expected catalyst delays rather than resolution.